Adjunctive, low-dose intracoronary recombinant tissue plasminogen activator (tPA) versus placebo for primary PCI in patients with ST-segment elevation myocardial infarction.
STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing major adverse cardiovascular events. STRIVE will assess the efficacy of a novel approach to prevent and treat microvascular obstruction and reduce major cardiovascular events using intracoronary administration of very low-dose fibrinolytic (tissue plasminogen activator, tPA) directly into the culprit coronary artery during primary PCI.
The objective is to determine if low-dose adjunctive intracoronary tPA (10 mg or 20 mg) will reduce the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization in patients undergoing primary PCI for STEMI.
Prospective, 3-arm, parallel group, open label, randomized controlled trial
Composite of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.